Business Wire

MO-BENSON-HILL

18.1.2023 13:01:35 CET | Business Wire | Press release

Share
Benson Hill Achieves ProTerra Sustainability Certification for its Proprietary Non-GMO Soy Portfolio

Benson Hill, Inc. (NYSE: BHIL, the “Company” or “Benson Hill”), a food tech company unlocking the natural genetic diversity of plants, announced today that it became one of the first U.S.-based ingredient providers to achieve the international ProTerra Certification, a rigorous global standard that sets the bar for sustainable agricultural practices and labor practices as well as segregated non-GMO programs and more. Benson Hill also joins the respected ProTerra Network, a group of companies dedicated to sustainable practices and continuous improvement.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230118005254/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Benson Hill Achieves ProTerra Sustainability Certification for its Proprietary Non-GMO Soy Portfolio. The company is one of the first U.S.-based ingredient providers to verify its sustainable practices under rigorous global standard. (Photo: Business Wire)

The ProTerra Certification program promotes social and environmental sustainability through food and feed supply chains, to support efforts to continuously improve day-to-day business operations and to help organizations to engage and implement the concept of sustainable development.

Throughout an extensive certification process, Benson Hill completed audits of its Creston, Iowa, and Seymour, Ind., plants as well as two shipping ports that store and transport its non-GMO soymeal. Benson Hill also partnered with its growers to conduct several on-farm visits. These in-depth audits examined data related to identity preservation along with deforestation practices, biodiversity efforts, and other Environmental, Social and Governance (ESG) metrics such as fair labor practices.

“I am delighted to welcome Benson Hill as a ProTerra Network Member. This certification demonstrates their engagement to continuously improve agricultural practices and achieve full transparency in the food supply chain,” said Emese van Maanen, Managing Director for the ProTerra Foundation. “Collaboration with farmers is essential to developing long-term relationships that create benefits from plant to plate.”

“Through our journey with ProTerra we gained important insights to solidify our position as a global ingredients company focused on responsible growth,” said Andres Martin, Executive Vice President and General Manager, International for Benson Hill. “Achieving the ProTerra certification standard is a testament to the ESG principles guiding our work to sustainably deliver our non-GMO soybean portfolio to markets within and outside the United States.”

The ProTerra standard, against which organizations are certified, is based on the Basel Criteria for Responsible Soy (created by Coop Switzerland and World Wildlife Fund). Today the standard is applicable to all sectors of the food and agricultural system worldwide and at all stages of the food chain. In addition, ProTerra certification ensures that high quality supplies of crops, food, and feed, that are independently certified as non-GMO and produced with improved sustainability, are available on the global market. Benson Hill’s proprietary soy ingredient portfolio, designed to meet specific end uses with less processing and increased traceability, is currently available in North America and in Europe.

Benson Hill built its closed-loop business model on sustainable design and systems thinking, which means its products deliver benefits across the entire value chain, from seed to plate. For example, CleanCRUSH™ ingredients derived from the company’s proprietary soybean genetics are designed as a less-processed alternative to commodity soy protein concentrate (SPC). CleanCRUSH ingredients can also reduce the need for costly energy- and water-intensive protein concentrating steps traditionally required for plant-based protein and aquaculture feed applications. In SPC comparisons, this can result in up to a 50 to 90 percent reduction in CO2e, depending on the ingredient source, and up to a 70 percent reduction in water usage.

For more information about Benson Hill’s progress in assessing impact and setting the pace of innovation in food, download its inaugural Environmental, Social and Governance (ESG) Report released in July 2022.

About Benson Hill

Benson Hill moves food forward with the CropOS® platform, a cutting-edge food innovation engine that combines data science and machine learning with biology and genetics. Benson Hill empowers innovators to unlock nature’s genetic diversity from plant to plate, with the purpose of creating nutritious, great-tasting food and ingredient options that are both widely accessible and sustainable. More information can be found at bensonhill.com or on Twitter at @bensonhillinc.

About ProTerra Foundation

The ProTerra Foundation is a not-for-profit organization located in the Netherlands that advances and promotes sustainability at all levels of the feed and food production system. Its mission is to be a global network of businesses supporting more sustainable agricultural practices in the agribusiness supply chains. The ProTerra Standard has been developed to promote social and environmental sustainability through the food and feed supply chains, to support stakeholders in their efforts to continuously improve their day-to-day business and to help organizations in engaging and implementing the concept of sustainable development. For details, please visit www.proterrafoundation.org.

Cautionary Note Regarding Forward-Looking Statements

Certain statements in this press release may be considered “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally relate to future events or the Company’s future financial or operating performance and may be identified by words such as “may,” “should,” “expect,” “intend,” “will,” “estimate,” “anticipate,” “believe,” “predict,” or similar words. These forward-looking statements are based upon assumptions made by the Company as of the date hereof and are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements include, among other things, statements regarding: the anticipated benefits of the Company’s ProTerra certification, ongoing sustainability and ESG initiatives, and farmer collaborations; the Company’s plans to promote sustainable agricultural practices and enhanced food supply chain transparency; anticipated advantages of the Company’s CleanCRUSH ingredients, including expectations regarding reduced carbon emissions and water usage; industry conditions and trends; the Company’s strategy and plans for growth; the expected future performance of and demand for the Company’s products; the Company’s ability to manage, develop and sustainably deliver its products to domestic and international markets; expectations about the markets in which the Company participates; and statements regarding the Company’s competitive positioning, resources, capabilities, and expectations for future performance. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, risks associated with: the Company’s ability to realize the expected benefits of its ProTerra certification and to maintain its ProTerra certification; the Company’s ability to realize benefits associated with its ongoing sustainability and ESG initiatives and farmer collaborations; the success of the Company’s products and their ability to achieve expected results, including results related to sustainability benefits; the Company’s ability to grow and achieve growth profitably; the Company’s ability to maintain relationships with its customers, suppliers and strategic partners; changing industry conditions and consumer preferences; the Company’s ability to retain key personnel and generally execute on its business strategy; global and regional economic, agricultural, financial and commodities markets; political, social and health conditions, both domestically and internationally; the Company’s transition to becoming a public company; the effectiveness of the Company’s risk management strategies; and other risks and uncertainties set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in our filings with the Securities and Exchange Commission (“SEC”), which are available on the SEC’s website at www.sec.gov. We expressly disclaim any duty to update these forward-looking statements, except as otherwise required by law.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230118005254/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release

Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release

Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie

IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release

IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi

Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release

Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M

Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release

Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye